Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities

PURPOSE: Anti-PD1 and PD-L1 antibodies are associated with immune-related adverse effects (irAEs). This analysis aims to assess the discrepancies between frequencies of irAEs observed in phase 1 trials with those seen in late-phase trials and to evolve the field of drug development. METHODS: PubMed...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Ricardo, Costa, Rubens B., Talamantes, Sarah M., Helenoswki, Irene, Carneiro, Benedito A., Chae, Young Kwang, Gradishar, William J., Kurzrock, Razelle, Giles, Francis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620211/
https://www.ncbi.nlm.nih.gov/pubmed/28978071
http://dx.doi.org/10.18632/oncotarget.18847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620211/
https://www.ncbi.nlm.nih.gov/pubmed/28978071
http://dx.doi.org/10.18632/oncotarget.18847

Ejemplares similares